TemelJS, GreerJA, MuzikanskyA, et al.Early palliative care for patients with metastatic non–small-cell lung cancer. N Engl J Med, 2010; 363(8):733–742; doi: 10.1056/NEJMoa1000678
KudohS, TakedaK, NakagawaK, et al.Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol, 2006; 24(22):3657–3663; doi: 10.1200/JCO.2006.06.1044
4.
YoneshimaY, MoritaS, AndoM, et al.Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol, 2021; 16(9):1523–1532; doi: 10.1016/j.jtho.2021.03.027
NokiharaH, LuS, MokTSK, et al.Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol, 2017; 28(11):2698–2706; doi: 10.1093/annonc/mdx419
7.
LeNS, ZeybekA, HacknerK, et al.Systemic anticancer therapy near the end of life: An analysis of factors influencing treatment in advanced tumor disease. ESMO Open, 2024; 9(9):103683; doi: 10.1016/j.esmoop.2024.103683
8.
MartinA, CartonM, TheryL, et al.Palliative care integration and end-of-life care intensity for patients with NSCLC. Lung Cancer, 2024; 192(April):107800; doi: 10.1016/j.lungcan.2024.107800
9.
MiyashitaM, MoritaT, SatoK, et al.Good death inventory: A measure for evaluating good death from the bereaved family member’s perspective. J Pain Symptom Manage, 2008; 35(5):486–498; doi: 10.1016/j.jpainsymman.2007.07.009
